Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081028 · ClinicalTrials.gov registry record
Connect® MM- The Multiple Myeloma Disease Registry
A clinical trial, sponsored by Celgene.
- Terminated
- Registry status
- 3,011
- Enrollment target
NCT01081028 is a clinical trial that was terminated before completion, run by Celgene. The registered enrollment target is 3,011 participants.
The verdict
NCT01081028 was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- 3,011 participants
- Enrollment target
Study Summary
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.
Interventions
- OTHER First-line therapy
- DRUG Second-line Multiple Myeloma treatments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,011 participants |
| Start Date | 2009-09-01 |
| Est. Completion | 2024-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01081028
The ClinicalTrials.gov registry entry for NCT01081028 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3,011 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which First-line therapy is the first listed.
NCT01081028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01081028 about?
NCT01081028 is a clinical study titled "Connect® MM- The Multiple Myeloma Disease Registry". The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.
What is the current status of trial NCT01081028?
This trial is currently terminated. The enrollment target is 3,011 participants. The study started on 2009-09-01. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT01081028?
The interventions under investigation include: First-line therapy (OTHER), Second-line Multiple Myeloma treatments (DRUG).
Who is sponsoring clinical trial NCT01081028?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.